Glioblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• TERT 3
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$401,115 awarded in fiscal year 2026· until Aug 2028

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$78,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R42

  Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

  Crimson Biopharm Inc· Brookline, United States· US$1,125,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Co-engineering CAR T cells and CAR macrophages with synthetic cytokine signaling for glioblastoma immunotherapy

  Stanford University· Stanford, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R21

  Regulation of Glioma Cell State Transition and Therapy Response by RNA Alternative Splicing

  Medical University of South Carolina· Charleston, United States· US$188,750 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €226,421· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Switzerland· EU contribution €292,119· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Netherlands· EU contribution €2,099,257· until May 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,484,173· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Germany· EU contribution €4,379,817· until Dec 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 821 running projects, newest first. Listed amounts together: US$403.5m + €179.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Surgical Nivolumab And Ipilimumab For Recurrent GBM

  NCT04606316· Gilbert Youssef· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers.

  Front Immunol, Sept 2026

• [Research of interaction of fluorescent anti-CD133 DNA aptamers with glioblastoma cell cultures using flow cytometry].

  Zh Vopr Neirokhir Im N N Burdenko, Jan 2026

• Isolation and Flow Cytometric Analysis of Natural Killer Cells from Human Glioblastoma Multiforme (GBM) Tissues.

  Curr Protoc, Nov 2025

• Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.

  Eur J Pharm Biopharm, Aug 2016

• Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells.

  J Pineal Res, Sept 2014

• Gracilaria lemaneiformis polysaccharide as integrin-targeting surface decorator of selenium nanoparticles to achieve enhanced anticancer efficacy.

  ACS Appl Mater Interfaces, Aug 2014

• Recombinant receptor-binding domain of diphtheria toxin increases the potency of curcumin by enhancing cellular uptake.

  Mol Pharm, Nov 2013

• Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells.

  FEBS J, May 2012

• Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy.

  Acta Biomater, Apr 2012

• Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest.

  Free Radic Biol Med, Feb 2012

See which targets of this disease your abstract mentions, and go to the people working on them.